Epigallocatechin gallate enhances sympathetic heart rate variability and decreases blood pressure in obese subjects.
Epigallocatechin gallate enhances sympathetic heart rate variability and decreases blood pressure in obese subjects: a randomized control trial.
AI Summary
Key Findings
Abstract
This study aimed to investigate effects of epigallocatechin gallate (EGCG) on blood pressure (BP) and autonomic nervous system, indicated by 5-min heart rate variability (HRV) measurement in obese subjects, and determine correlations of BP with metabolic factors. In a double-blind, randomized controlled trial, obese subjects (n = 30) were randomly allocated to receive 150 mg EGCG (n = 15) or placebo (n = 15) twice a day without dietary restrictions. After 8-week EGCG treatment, systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean arterial pressure (MAP) significantly decreased, while the low-frequency (LF) to high-frequency power (HF) ratio (LF/HF ratio) significantly increased (P
Affiliation
Kittikorn Tommy Wilasrusmee
External References
- PubMed ID:
- 39285220
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.